<DOC>
	<DOCNO>NCT01313598</DOCNO>
	<brief_summary>The purpose study determine safety tolerability GLPG0187 administer continuous intravenous infusion explore preliminary clinical efficacy patient solid tumor .</brief_summary>
	<brief_title>GLPG0187 : Safety , Tolerability Pharmacokinetics Patients With Solid Tumors</brief_title>
	<detailed_description>Patients pathologically confirm diagnosis advance , recurrent , metastatic cancer refractory standard therapy standard therapy exist first receive one-hour infusion define dose GLPG0187 . If well tolerate , one week later three-week continuous infusion start . If accord investigator subject clinical benefit treatment GLPG0187 , treatment cycle may repeat disease progression , Dose Limiting Toxicity ( DLT ) , patient chooses stop /will comply study procedure . Throughout treatment , safety tolerability monitor . Within one patient , fix dose ( infusion rate ) use . If give dose-level sufficient patient treat without reach DLT , dose next group patient increase . This repeat DLT establish , schedule maximum dosage reach .</detailed_description>
	<criteria>Pathologically confirm diagnosis advance , recurrent , metastatic cancer refractory standard therapy standard therapy exist . Age 18 year old . Measurable ( accord RECIST 1.1 ) evaluable disease determine Investigator . ECOG Performance Status ≤ 2 . Estimated life expectancy least 12 week . Toxicities incur result previous anticancer therapy ( radiation therapy , chemotherapy , surgery ) must resolve ≤ Grade 2 . Written inform consent accord local guideline . Prior Treatment : Less 4 week since last treatment cancer therapy , ( i.e . endocrine therapy , immunotherapy , chemotherapy , etc . ) , &lt; 6 week nitrosoureas Mitomycin C. Prior therapy integrin receptor antagonists Current Treatment : Chronic daily treatment corticosteroid ( dose 10 mg/day methylprednisolone equivalent ) , exception inhale steroid . Current recent ( within 30 day first study treatment ) treatment another investigational drug participation another investigational study . Hematology , coagulation biochemistry : Inadequate bone marrow function : Absolute Neutrophil Count ( ANC ) : &lt; 1.5 x 10E9/L , platelet count &lt; 100 x 10E9/L hemoglobin &lt; 6 mmol/L . Inadequate liver function , define : Serum ( total ) bilirubin &gt; 2 x Upper Limit Normal ( ULN ) institution ; Aspartate Amino Transferase ( ASAT ) Alanine Amino Transferase ( ALAT ) &gt; 2.5 x ULN ( &gt; 5 x ULN subject liver metastasis ) ; Alkaline phosphatase level &gt; 2.5 x ULN ( &gt; 5 x ULN subject liver metastasis , &gt; 10 x ULN subject bone metastasis ) . Inadequate renal function , define : Serum creatinine &gt; 1.5 x ULN Urine dipstick proteinuria &gt; 2+ . Other : Clinically symptomatic progressive brain metastasis Clinical Leptomeningeal metastases Pregnancy lactation . Serum pregnancy test assess within 7 day prior study treatment start , within 14 day confirmatory urine pregnancy test within 7 day prior study treatment start . For woman childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) : absence effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal gel ) . Major surgical procedure ( include open biopsy , exclude central line IV portacath ) within 28 day prior first study treatment , anticipation need major surgery course study treatment . Congestive heart failure NYHA Class III IV . Cardiac arrhythmia ( except atrioventricular block type I , Mobitz type , II , Wenckebach type ) sign symptom relevant cardiovascular disease . Known hypersensitivity study drug excipients . Evidence medical condition ( psychiatric illness , infectious disease , physical examination laboratory finding ) may interfere plan treatment , affect subject compliance place subject high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Patients solid tumor</keyword>
	<keyword>Treatment-refractory</keyword>
</DOC>